Zentalis Pharmaceuticals, Inc. (NASDAQ: ZNTL) has chosen 400 mg once‑daily on a 5‑days‑on, 2‑days‑off schedule (400 mg QD 5:2) as the pivotal monotherapy dose for its investigational WEE1 inhibitor azenosertib in patients with Cyclin E1‑positive platinum‑resistant ovarian cancer (PROC).
The decision followed a prespecified interim analysis of DENALI Part 2a, which compared 400 mg QD 5:2 to 300 mg QD 5:2. The interim data showed a differentiated objective response rate—objective response rates above 30% for the 400 mg cohort—alongside comparable safety profiles, with discontinuation rates due to adverse events roughly half those seen in DENALI Part 1b and no treatment‑related deaths.
By adopting the 400 mg QD 5:2 dose, Zentalis streamlines its clinical development path, positioning the drug for a potential accelerated‑approval strategy. The selected dose will be used in the ongoing DENALI Phase 2 trial and the confirmatory ASPENOVA Phase 3 study, which is slated to begin in Q2 2026, with DENALI Part 2 topline readout expected by year‑end 2026.
Zentalis reported a GAAP earnings per share of –$0.49 for Q4 2025, missing consensus estimates of –$0.41 by $0.08, while maintaining a strong liquidity position with $245.9 million in cash, cash equivalents, and marketable securities and a current ratio of 6.93 that supports a runway into late 2027.
CEO Julie Eastland said, ‘Selecting the pivotal monotherapy dose for azenosertib is a key inflection point that supports our registration‑intended path. Beyond executing on DENALI and ASPENOVA, we are initiating launch preparedness by adding commercial capabilities to our organization, scaling manufacturing capacity, and advancing companion diagnostic development.’ She added, ‘Importantly, the therapeutic profile of the selected dose from the DENALI Part 2a interim analysis provides us confidence to further pursue expansion of the clinical pipeline for azenosertib into first‑line maintenance, or platinum‑sensitive, ovarian cancer and explore combinations in new tumor types.’
Chief Medical Officer Ingmar Bruns noted, ‘The emerging DENALI Part 2a data from the planned interim analysis provide a favorable benefit‑risk profile at the 400mg QD 5:2 dose over 300mg QD 5:2. A meaningful, differentiated response rate with the selected dose and comparable safety profiles across both dose groups were observed in this interim analysis.’ Investors reacted positively to the announcement, reflecting confidence in the drug’s development trajectory.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.